Adapt Pharma Urges FDA Hurdles For Teva Overdose Generic

Law360, New York (November 18, 2016, 7:12 PM EST) -- Adapt Pharma wants the U.S. Food and Drug Administration to require Teva’s generic version of overdose drug Narcan to undergo special scrutiny in order to win approval, according to a newly released citizen petition.

The petition, released Thursday, targets a proposed generic from Teva Pharmaceutical Industries Ltd., which Adapt is already suing for patent infringement, as well as any other generics of Narcan. The brand-name product is a nasal spray that delivers rescue doses of naloxone to patients who overdose on opioids, such as heroin or oxycodone.

It’s common for brand-name drugmakers to file citizen petitions that urge the FDA to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!